MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
BeiGene, Ltd. DIO Ratio 2011-2026 | BGNE
Annual DIO Ratio BeiGene, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 304 | 10.4 | 8.38 | 14.6 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 304 | 8.38 | 84.4 |
Quarterly DIO Ratio BeiGene, Ltd.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 302 | 294 | 323 | - | 330 | 326 | 341 | - | 258 | 240 | 227 | - | 386 | 570 | 380 | - | 130 | 146 | 134 | - | 170 | 237 | 272 | - | 513 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 570 | 130 | 294 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.82 | -2.95 % | $ 4.47 M |  China |
 |
Axsome Therapeutics
AXSM
|
168 | $ 165.96 | -0.25 % | $ 8.26 B | USA |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Codexis
CDXS
|
50.2 | $ 0.97 | -4.87 % | $ 71.2 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
119 | $ 24.04 | 0.67 % | $ 2.94 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
DBV Technologies S.A.
DBVT
|
332 | $ 21.89 | -5.85 % | $ 2.12 B |  France |
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K | USA |
 |
Eton Pharmaceuticals
ETON
|
25.3 | $ 17.52 | -3.47 % | $ 449 M | USA |
 |
Exelixis
EXEL
|
96.1 | $ 40.72 | -0.76 % | $ 11.1 B | USA |
 |
Acasti Pharma
ACST
|
136 | - | 4.01 % | $ 150 M |  Canada |
 |
Amicus Therapeutics
FOLD
|
870 | $ 14.35 | -0.1 % | $ 4.43 B | USA |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M | Canada |
 |
Galapagos NV
GLPG
|
0.915 | $ 32.94 | -3.37 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.54 | -6.11 % | $ 6.83 B |  Spain |
 |
Halozyme Therapeutics
HALO
|
254 | $ 69.01 | -1.2 % | $ 8.27 B | USA |
 |
Agenus
AGEN
|
0.163 | $ 3.17 | -5.09 % | $ 1.13 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.74 K | $ 28.49 | -2.57 % | $ 1.65 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
11.6 | $ 28.56 | -1.18 % | $ 1.64 B | USA |